EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ANI Pharmaceuticals's enterprise value is $1,942.7 Mil.
ANI Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $674.1 Mil. Therefore, ANI Pharmaceuticals's EV-to-Revenue for today is 2.88.
The historical rank and industry rank for ANI Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ANIP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.19 Med: 3.38 Max: 10.07
Current: 2.88
During the past 13 years, the highest EV-to-Revenue of ANI Pharmaceuticals was 10.07. The lowest was 2.19. And the median was 3.38.
ANIP's EV-to-Revenue is ranked worse than 56.38% of 972
companies
in the Drug Manufacturers industry
Industry Median: 2.405
vs ANIP: 2.88
The historical data trend for ANI Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ANI Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's EV-to-Revenue falls into.
ANI Pharmaceuticals's current Enterprise Value is $1,942.7 Mil.
ANI Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $674.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (NAS:ANIP) EV-to-Revenue Explanation
ANI Pharmaceuticals's share price for today is $66.98.
ANI Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ANI Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANIP has been successfully added to your 